

Mayla Sgrulletti, MD, PhD

✉ maylasg@gmail.com

Gender F | Date of Birth 1 Nov 1990 | Nationality Italy

Pediatric Allergist and Clinical Immunologist

- 13th Apr 2022 - current **Pediatric Allergist and Clinical Immunologist**
Pediatric Immunopathology and Allergology Unit - Policlinico Tor Vergata – Rome, Italy
- 24th Oct 2024 **PhD in Immunology, Molecular Medicine and Applied Biotechnologies**
University of Rome Tor Vergata
Pediatric Immunopathology and Allergology Unit - Policlinico Tor Vergata – Rome, Italy
- 23th Sept 2021- current **Teaching Assistant role for “Pediatric Sciences” for Medicine and Surgery Degree Course**
University of Rome Tor Vergata
- 2022 Jan- 2022 Apr **Research Contract**
Bambino Gesù Children’s Hospital - Immunopathology and Allergology Unit - Policlinico Tor Vergata – Rome, Italy
Research Area “Conect4Children -Collaborative Network for European Clinical Trials for Children, C4C ”
- 2021 **Research Contract**
Bambino Gesù Children’s Hospital - Immunopathology and Allergology Unit - Policlinico Tor Vergata – Rome, Italy
Research Area “Infectious diseases and pediatric drug development”
- 2020 –2021 **Teaching Assistant role for “General and Specialized Pediatrics”**
Unicamillus – Saint Camillus International University of Health Sciences
Nursing - Physiotherapy - Maternal Childcare Obstetrics
- 26th Oct 2020 **Specialization in Allergy and Clinical Immunology**
70/70 cum laude
“Sapienza” University of Rome, Italy

23th Jul 2015

Medicine and Surgery Degree

110/110 cum laude

University of Rome Tor Vergata, Italy

MD thesis: Follow-up and outcome of symptomatic partial or absolute IgA deficiency in children

Pediatric Internship

2013-2015 Pediatric Immunopathology and Allergology Unit - Policlinico Tor Vergata – Rome, Italy

MOTHER TONGUE Italian

FOREIGN LANGUAGE

Inglese

UNDERSTANDING		SPEAKING		WRITING
Listening	Reading	Spoken interaction	Spoken production	
B2	B2	B2	B2	B2

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user
Common European Framework of Reference for Languages - Self-assessment grid

2021 Oct: Cambridge Assessment English FIRST – Level B2

ADDITIONAL INFORMATION

Membership

- Junior Member of the Italian Society of Pediatric Allergy and Immunology (SIAIP) Vaccine Committee (2020 -)
- Active panelist member for B cell Inborn Errors of Immunity (IEI) of the Italian Network for Primary Immunodeficiency (IPINet) (2020 -)
- Active member of the IEI Virtual Consultation System platform (2020 -)
- Italian Society of Pediatric Research (SIRP) treasurer (2024 -)

Clinical Trials

- Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety and Pharmacokinetics of Kedrion Intravenous Human Normal Immunoglobulin (IVIg) 10% in Pediatric Patients Affected by Primary Immunodeficiency Disease (PID).
Sub-investigator, 2020
- NORM-01, Prospective, Open-Label, Single-Arm, Multicentre Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients with Primary Immunodeficiency Diseases.
Sub-investigator, 2024